Medanta's Q3 FY26: A Quarter of Robust Growth and Strategic Expansion

Global Health Limited, operating under the renowned Medanta brand, has reported a strong performance for the third quarter of fiscal year 2026, showcasing significant growth and strategic advancements. The company's total income surged by an impressive 19.1% year-on-year, reaching INR 1,142.8 crore. This robust growth was primarily fueled by sustained momentum across its hospital network, coupled with notable improvements in operating metrics. While the newly operational Noida facility presented initial operating losses, the overall picture reflects Medanta's resilient business model and its commitment to expanding its footprint and enhancing clinical excellence.

Operational Momentum and Patient-Centric Growth

Medanta's operational performance in Q3 FY26 was marked by a significant increase in patient volumes and improved efficiency. In-patient volumes grew by 14.3% year-on-year, while out-patient volumes saw an even higher jump of 19.5%. This indicates strong patient trust and increasing demand for Medanta's specialized healthcare services. The Average Revenue Per Occupied Bed (ARPOB) also rose by 9.9% to INR 67,361, driven by improvements in Average Length of Stay (ALOS) and a favorable case mix. The ALOS improved by 6.6% year-on-year, settling at 3.02 days, reflecting enhanced operational efficiency.

The Noida facility, which commenced operations in September 2025, completed its first full quarter, generating INR 34.3 crore in revenue. Despite an initial EBITDA loss of INR 32 crore, management expressed confidence in its ramp-up trajectory, expecting steady improvement in utilization and financial performance in the coming quarters. The company also highlighted strong growth in its international patient revenue, which increased by 29.9% year-on-year, and its OPD pharmacy business, which grew by 30.3%.

Here's a snapshot of Medanta's Q3 FY26 financial performance:

Strategic Expansion and Technological Advancements

Medanta's growth strategy extends beyond operational efficiencies to aggressive capacity expansion and technological integration. The company added 144 beds in Q3 FY26, contributing to a total of 537 beds added in the first nine months of FY26. This includes significant additions in Patna (42 beds) and Noida (102 beds), bringing Noida's total bed capacity to 328.

Looking forward, Medanta has ambitious plans to add approximately 2,300 more beds across new projects and brownfield expansions. Key upcoming projects include super-specialty hospitals in South Delhi (~400 beds), Pitampura, New Delhi (~750 beds), Oshiwara, Mumbai (750+ beds), and Guwahati (400+ beds). These expansions are strategically aimed at penetrating high-growth, densely populated micro-markets across North and East India.

Technological advancements remain a core focus. Medanta operationalized its 5th Radiation Oncology Machine in Gurugram and deployed a suite of advanced medical technologies in Noida, including O-arm O2 Surgical Imaging, SOMATOM Pro. Pulse Dual Source CT, ARTIS icono BiPlane CATH Lab, MAGNETOM Lumina 3T MRI, Da Vinci Xi Robotic System, and Leica Arveo 8 Digital Visualisation Microscope for Neurosurgery. These investments underscore Medanta's commitment to delivering cutting-edge medical care.

Talent Acquisition and Future Outlook

Recognizing the critical role of human capital, Medanta actively recruited 110 doctors across its network in Q3 FY26, with over 70 specifically for the Noida facility. This talent acquisition strategy focuses on key clinical departments like Cardiac, Critical Care, and Cancer, ensuring sustained high-quality care and supporting the ramp-up of new facilities. Furthermore, Medanta's Lucknow facility received the prestigious Joint Commission International (JCI) quality accreditation in January 2026, reinforcing its commitment to global standards of clinical quality and patient safety.

Management provided a positive outlook, guiding for an ARPOB growth of 5% to 7% annually in the medium term. They anticipate next year's CAPEX (FY27) to be below INR 500 crore, with major investments in new projects back-ended towards two to three years from now. The company also aims to achieve significant operational efficiencies, targeting a couple of hundred basis points of improvement across various cost items. Medanta's strategic clarity, disciplined execution, and continuous investment in infrastructure, technology, and talent position it for sustained growth and leadership in the Indian healthcare sector.